![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Merck KGaA, Sysmex Inostics Nab CE Mark for Colorectal Cancer Test
Merck KGaA, Sysmex Inostics Nab CE Mark for Colorectal Cancer Test
![correct_handshake.gif](https://www.fdanews.com/ext/resources/test/Device_Images/handshake.gif?t=1576815772&width=430)
Merck KGaA and Sysmex Inostics’ jointly developed liquid biopsy OncoBEAM RAS CRC assay has garnered CE marking.
Comparable to tissue-based testing, the test can identify which patients with metastatic colorectal cancer are more receptive to anti-epidermal growth factor receptor therapies, like Erbitux, according to a statement.
The assay consists of a 34-mutation panel based on beads, emulsion, amplification and magnetics technology, and only requires a 10 ml blood sample. — Anisa Jibrell
Upcoming Events
-
11Jul
-
18Jul
-
21Oct